Ovarian Cancer Statistics

Survival Rates

Survival rates can be calculated by different methods for different purposes. The ovarian cancer survival rates presented here are based on the relative survival rate. The relative survival rate measures the survival of cancer patients in comparison to the general population to estimate the effect of cancer. The overall 5-year relative survival rate for ovarian cancer for 1996-2002 was 44.7 percent. The 5-year relative survival rates by race and sex were:
 
  • 44.2 percent for white women
  • 39.5 percent for black women.
     

How Stage Affects Survival

The stage of ovarian cancer a woman has plays a role in her ovarian cancer prognosis. Based on historical data:
 
  • 19 percent of ovarian cancer cases are diagnosed while the cancer is still confined to the primary site (localized stage)
  • 7 percent of ovarian cancer cases are diagnosed after the cancer has spread to regional lymph nodes or directly beyond the primary site
  • 68 percent of ovarian cancer cases are diagnosed after the cancer has already metastasized (distant stage)
  • 7 percent of ovarian cancer cases had staging information that was unknown.
     
The corresponding 5-year relative ovarian cancer survival rates were:
 
  • 93.1 percent for localized
  • 69.0 percent for regional
  • 29.6 percent for distant
  • 23.3 percent for unstaged.
     

Statistics on Lifetime Risk

Based on rates from 2001-2003, 1.44 percent of women (or 1 in 69 women) born today will be diagnosed with ovarian cancer at some point during their lifetime. These statistics are called the lifetime risk of developing cancer.
 
7 Natural Ways to Reduce Your Cancer Pain
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.